Literature DB >> 29602915

Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.

Diana Ferraro1, Valentina Camera2, Francesca Vitetta2, Mauro Zennaro2, Ludovico Ciolli2, Paolo Frigio Nichelli2, Patrizia Sola2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29602915     DOI： 10.1212/WNL.0000000000005417

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  2 in total

1.  Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.

Authors:  Alasdair J Coles; Douglas L Arnold; Ann D Bass; Aaron L Boster; D Alastair S Compston; Óscar Fernández; Eva Kubala Havrdová; Kunio Nakamura; Anthony Traboulsee; Tjalf Ziemssen; Alan Jacobs; David H Margolin; Xiaobi Huang; Nadia Daizadeh; Madalina C Chirieac; Krzysztof W Selmaj
Journal:  Ther Adv Neurol Disord       Date:  2021-04-23       Impact factor: 6.570

2.  Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.

Authors:  Ilkka Rauma; Tiina Mustonen; Juha Matti Seppä; Maritta Ukkonen; Marianne Männikkö; Auli Verkkoniemi-Ahola; Marge Kartau; Jukka T Saarinen; Liisa Luostarinen; Sakari Simula; Mervi Ryytty; Riitta Ahmasalo; Jussi O T Sipilä; Ilkka Pieninkeroinen; Tero Tapiola; Anne M Remes; Hanna Kuusisto
Journal:  J Neurol       Date:  2021-07-13       Impact factor: 4.849
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.